11:03:38 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-04-17 Ordinarie utdelning NANOFH 0.00 EUR
2024-04-16 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-04-13 Ordinarie utdelning NANOFH 0.00 EUR
2023-04-12 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-29 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-13 Ordinarie utdelning NANOFH 0.00 EUR
2022-04-12 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-11-17 Extra Bolagsstämma 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-27 Kvartalsrapport 2021-Q1
2021-04-07 Ordinarie utdelning NANOFH 0.00 EUR
2021-04-06 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-09-01 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nanoform Finland är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av tekniska produkter som används för att skapa nanopartiklar i läkemedel. Tekniken används som komplement i produktionsprocessen och används för behandling av sjukdomar som ALS och Alzheimers. Kunderna består av aktörer inom den globala läkemedelsindustrin. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingfors.
2021-11-17 09:15:00

Press release

Nanoform Finland Plc

November 17, 2021

10:15 a.m. Finnish time / 09:15 a.m. Swedish time

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has won the Star of Innovation award at the 9[th] annual European Small and Mid-Cap Awards. The award win recognizes Nanoform as a listed company that places innovation at the center of its strategy for business development and introduces an innovative technology to the market. On the same night, 16[th] November 2021, Nanoform were also shortlisted for two further awards at the European Mediscience Awards which took place in London. This was a great accolade as many of the award winners were rightly recognized for their outstanding contribution to COVID such as AstraZeneca and BioNTech. To be in the presence of industry drug development giants shows that small continues to be powerful.

The European Small and Mid-Cap Awards, launched in 2013, were established by the European Commission to recognize selected European listed growth companies. EuropeanIssuers, who represent listed companies, and the Federation of European Securities Exchanges (FESE), who represent European stock exchanges, are co-organizers of the event.

Nanoform, listed on Nasdaq, was shortlisted out of 27 nominations from 17 countries, listed on different European stock exchanges.

Prof. Edward Hæggström, Nanoform CEO, commented: "We are honored to have received the Star of Innovation award within European Small and Mid-Cap Awards 2021. Patients' lives depend on innovation, and they are at the heart of all that we do in Nanoform. We would like to thank the European Commission, EuropeanIssuers and the Federation of European Securities Exchanges for recognizing our innovation, Nasdaq IPO, job creation and speed of growth. European capital markets are highly efficient, and we are grateful for the endorsement. In future, we look forward to continue being an important part of the European growth engine."

For further information, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com/ +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information please visit http://www.nanoform.com